KROS
NASDAQ · Biotechnology

Keros Therapeutics Inc

$11.49
+0.37 (+3.33%)
As of May 9, 1:46 AM ET ·
Financial Highlights (FY 2026)
Revenue
129.23M
Net Income
46.07M
Gross Margin
Profit Margin
35.7%
Rev Growth
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 50.8% 50.8%
Operating Margin 27.7% -5,345.1% -16.0% -16.9%
Profit Margin 35.7% -5,013.7% -15.0% -17.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 129.23M 4.38M 103.26M 79.84M
Gross Profit 52.49M 40.58M
Operating Income 35.78M -233,970,055 -16,499,040 -13,532,511
Net Income 46.07M -207,966,613 -15,524,708 -13,846,639
Gross Margin 50.8% 50.8%
Operating Margin 27.7% -5,345.1% -16.0% -16.9%
Profit Margin 35.7% -5,013.7% -15.0% -17.3%
Rev Growth -43.9% +11.8% -2.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 173.40M 194.80M
Total Equity 374.54M 364.51M
D/E Ratio 0.46 0.53
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 36.29M -245,260,567 -22,220,211 -17,087,554
Free Cash Flow -17,331,210 -15,756,938